Acute respiratory distress syndrome therapeutic agent

A technology for acute respiratory distress syndrome, applied in the field of acute respiratory distress syndrome therapeutic agents, which can solve the problems of low stability and low tissue affinity

Active Publication Date: 2018-07-31
LTT BIO PHARMA
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] In addition, the isoenzyme (iso) type SOD (Cu / Zn-SOD) proposed as a derivative of gene recombinant SOD has also been used clinically, but its tissue affinity is low and its stability in plasma is low. thus unsuccessful

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acute respiratory distress syndrome therapeutic agent
  • Acute respiratory distress syndrome therapeutic agent
  • Acute respiratory distress syndrome therapeutic agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0105] Hereinafter, the present invention will be described in more detail by referring to test examples specifically studied by the present inventors by substituting Examples, but the present invention is not limited to these descriptions.

[0106]

[0107] LPS (lipopolysaccharide: lipopolysaccharide) was obtained from Escherichia coli and purchased from Sigma (St Louis, MO).

[0108] Diff-Quik was purchased by Sysmex Corporation (Kobe).

[0109] DRI-CHEM test pieces (for BUN identification) were purchased from Fujifilm Corporation.

[0110] L-012 (luminescent probe), LabAssay Creatinine Quantitative Kit, and Evans Blue were purchased from Wako Pure Chemical Industries.

[0111] Novo-Heparin (5000 units) was purchased by Mochida Pharmaceutical Company.

[0112] Pentobarbital was purchased from Tokyo Chemical Company.

[0113] ICR mice (6-7 weeks old) were purchased from Charles River Company.

[0114]

[0115] The mice were anesthetized with pentobarbital (10 mg / kg, i...

preparation example 1

[0227] Preparation Example 1: Intravenous Injection

[0228] 1% (w / w) PC-SOD, 10% (w / w) sucrose, and 0.05% (w / w) benzalkonium chloride were dissolved in 5% xylitol aqueous solution, and freeze-dried. To the obtained freeze-dried preparation, 0.5% carboxymethylcellulose or water for injection, which was separately filled in a vial, was added, whereby an intravenous injection preparation was obtained.

Embodiment 2

[0229] Example 2: Inhalation

[0230] Liquids for Inhalation (1)

[0231] A solution for inhalation was prepared by dissolving 1% (w / w) PC-SOD, 10% (w / w) sucrose, and 0.05% (w / w) benzalkonium chloride in 5% xylitol aqueous solution.

[0232] Liquids for Inhalation (2)

[0233] With 1% (w / w) PC-SOD, 10% (w / w) sucrose, 0.05% (w / w) benzalkonium chloride, 10% (w / w) polyethylene glycol, 20% (w / w) w) Propylene glycol and the remaining amount of pure water are used to prepare a liquid for inhalation.

[0234] powder for inhalation

[0235] A powder for inhalation was prepared with 5% (w / w) PC-SOD and the balance sucrose (fine powder).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is an acute respiratory distress syndrome therapeutic agent whose active ingredient is lecithinated superoxide dismutase represented by general formula (I): SOD'(Q-B)m (I) (in the formula, SOD' is a superoxide dismutase residue, Q is chemical crosslinking, B is a residue obtained by removing the hydrogen atom of the hydroxyl group in lysolecithin having a hydroxyl group at position 2 of the glycerol, and m is the average number of bonds of lysolecithin per 1 molecule of superoxide dismutase and is an integer of 1 or greater).

Description

technical field [0001] The present invention relates to a therapeutic agent for acute respiratory distress syndrome, and specifically relates to a treatment for acute respiratory distress syndrome comprising lecithinated superoxide dismutase (hereinafter sometimes referred to as "PC-SOD") as an active ingredient agent. Background technique [0002] Acute Respiratory Distress Syndrome (ARDS: Acute Respiratory Distress Syndrome, hereinafter sometimes referred to as "ARDS") is also called Acute Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome). One of the main reasons is a disease of considerable public health importance. The number of patients with ARDS reaches 200,000 in the United States every year. However, the reality is that no definitive treatment method has been established for this disease, and the mortality rate is quite high (40 to 50%). [0003] ARDS is a fatal clinical syndrome defined by edema, and acute hypoxic respiratory failure with cardiac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/44A61K47/26A61P11/00
CPCA61K38/44A61K47/26A61P11/00A61K38/446C12N9/0089C12Y115/01001A61K9/0019A61K9/0075A61K9/0078
Inventor 水岛徹
Owner LTT BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products